
    
      This research study is a Phase II clinical trial. Phase II clinical trials test the safety
      and effectiveness of an investigational drug to learn whether the drug works in treating a
      specific disease. "Investigational" means that the drug is being studied.

      The U.S. Food and Drug Administration (FDA) has not approved tazarotene for specifically for
      hand-foot skin reaction but it has been approved for other uses.

      In this research study, the investigators are:

      -aiming to determine if the use of tazarotene gel daily, in addition to best practice
      standards:

        -  reduces the development of HFSR.

        -  decreases modification of regorafenib dose due to HFSR

        -  improves health-related quality of life associated with HFSR

        -  decreases stress associated with HFSR
    
  